

Nile Therapeutics, Inc.  
 Form 5  
 February 12, 2010

# FORM 5

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0362  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).  
 Form 3 Holdings Reported Form 4 Transactions Reported

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person \*  
**TANEN DAVID M**  
 (Last) (First) (Middle)

2. Issuer Name and Ticker or Trading Symbol  
**Nile Therapeutics, Inc. [NLTX]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)  
**12/31/2009**

**C/O TWO RIVER GROUP HOLDINGS, LLC, 689 FIFT AVENUE, 12TH FLOOR**  
 (Street)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Reporting

(check applicable line)

**NEW YORK, NY 10022**  
 (City) (State) (Zip)

Form Filed by One Reporting Person  
 Form Filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or (D) Price	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
---------------------------------	--------------------------------------	--	--------------------------------	---	--	--	-----------------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 2270 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction	5. Number of Derivative	6. Date Exercisable and Expiration Date	7. Title and Amount of Underlying Security
------------------------	---------------	--------------------------------------	-----------------------------------	----------------	-------------------------	---	--

Edgar Filing: Nile Therapeutics, Inc. - Form 5

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	Title	Am or Num of S
				(A)	(D)	Date Exercisable	Expiration Date			
Stock Option (Right to Buy)	\$ 4.5	09/24/2009	Â	D4 <u>(1)</u>	Â 50,000	Â <u>(2)</u>	01/25/2018	Common Stock	50	
Stock Option (Right to Buy)	\$ 4.5	09/24/2009	Â	A4 <u>(1)</u>	50,000	Â Â <u>(1)</u>	09/24/2014	Common Stock	50	
Stock Option (Right to Buy)	\$ 0.93	09/24/2009	Â	D4 <u>(1)</u>	Â 25,000	Â <u>(1)</u>	12/22/2018	Common Stock	25	
Stock Option (Right to Buy)	\$ 0.93	09/24/2009	Â	A4 <u>(1)</u>	25,000	Â Â <u>(1)</u>	09/24/2014	Common Stock	25	
Stock Option (Right to Buy)	\$ 1.77	09/24/2009	Â	D4 <u>(1)</u>	Â 65,000	Â <u>(1)</u>	07/21/2019	Common Stock	65	
Stock Option (Right to Buy)	\$ 1.77	09/24/2009	Â	A4 <u>(1)</u>	65,000	Â Â <u>(1)</u>	09/24/2014	Common Stock	65	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TANEN DAVID M C/O TWO RIVER GROUP HOLDINGS, LLC 689 FIFT AVENUE, 12TH FLOOR NEW YORK, NY 10022	Â X	Â	Â	Â

## Signatures

/s/ David M. Tanen 02/12/2010

\*\*Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- The reported transactions involve amendments to previously granted stock options, resulting in the deemed cancellation of the "old" stock options and the grant of replacement stock options. In connection with the Reporting Person's resignation from the Board of Directors on September 24, 2009, the Company amended the stock options to provide for the acceleration of all unvested portions and to extend the exercise period to September 24, 2014. All stock options are exercisable as of September 24, 2009, the date of the amendments.
- (1) The stock option was originally granted on January 25, 2008, and provided for vesting in three equal installments on September 17, 2008, September 17, 2009, and September 17, 2010.
  - (2) The stock option was originally granted on January 25, 2008, and provided for vesting in three equal installments on September 17, 2008, September 17, 2009, and September 17, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.